CLEOPATRA sets new standard treatment paradigm for metastatic breast cancer

MADRID – First-line dual targeted therapy with pertuzumab and trastuzumab plus chemotherapy gives women with HER2-positive metastatic breast cancer an additional 15.7 months of life, according to the...